NCI Research Specialist (Clinician Scientist) Award

ABSTRACT Dr. Karyn Goodman plays a critical role in Tisch Cancer Institute’s (TCI) cancer clinical trial program and in supporting NCI-funded clinical trials. She has demonstrated a long-term commitment to this work through her previous role as Associate Director (AD) of Clinical Research for 3 years at the University of Colorado Cancer Center. In the same role in the TCI, Dr. Goodman has been able to further expand on the work she was doing in Colorado and has focused on five major goals: 1) to expand access to clinical trials across the Mount Sinai Health System (MSHS); 2) to increase the numbers of NCI-sponsored trials performed across the MSHS; 3) to address the need for more oversight and integration of clinical trial services provided across the MSHS; 4) to support junior faculty to develop investigator-initiated trials (IITs) and present concepts to the Experimental Therapeutic Clinical Trials Network (ETCTN) for potential support; and, 5) to increase minority recruitment to TCI clinical trials. Institutionally, she has been the local PI of numerous National Clinical Trials Network (NCTN) studies at several NCI-designated cancer centers and is currently the Mount Sinai PI for one ECOG/ACRIN trial and one ETCTN trial and serves as the PI for the Early Drug Development Opportunity Program (EDDOP) at Mount Sinai. In addition, she is a national leader in the NCTN both through her involvement in the GI committees of the Alliance for Clinical Trials in Oncology and the NRG Oncology, as well as her role as the co-chair of the NCI Gastrointestinal Steering Committee. She has nicely bridged the work she has done nationally with her institutional AD of Clinical Research position. She brings her expertise in clinical trial development and oversight which she gained as the National Study Chair of the CALGB/Alliance 80803, a Phase II trial that evaluated PET-directed therapy for esophageal cancer, and the National Radiation Oncology Principal Investigator of the RTOG/NRG 0848, a large Phase III trial investigating the role of adjuvant chemoradiation in resectable pancreas cancer. Her overarching goal as a senior leader in the TCI is to support the development of both IITs and NCI-funded cooperative group clinical trials that will further advance the fight against cancer. The R50 funding mechanism will undoubtedly help foster her ability to expand NCI-funded oncology clinical research at Mount Sinai Hospital and expand access to these trials across the MSHS. Dr. Goodman is uniquely positioned for this award with both her institutional and national service focused on developing and supporting cancer clinical research.

ABSTRACT Dr. Karyn Goodman plays a critical role in Tisch Cancer Institute’s (TCI) cancer clinical trial program and in supporting NCI-funded clinical trials. She has demonstrated a long-term commitment to this work through her previous role as Associate Director (AD) of Clinical Research for 3 years at the University of Colorado Cancer Center. In the same role in the TCI, Dr. Goodman has been able to further expand on the work she was doing in Colorado and has focused on five major goals: 1) to expand access to clinical trials across the Mount Sinai Health System (MSHS); 2) to increase the numbers of NCI-sponsored trials performed across the MSHS; 3) to address the need for more oversight and integration of clinical trial services provided across the MSHS; 4) to support junior faculty to develop investigator-initiated trials (IITs) and present concepts to the Experimental Therapeutic Clinical Trials Network (ETCTN) for potential support; and, 5) to increase minority recruitment to TCI clinical trials. Institutionally, she has been the local PI of numerous National Clinical Trials Network (NCTN) studies at several NCI-designated cancer centers and is currently the Mount Sinai PI for one ECOG/ACRIN trial and one ETCTN trial and serves as the PI for the Early Drug Development Opportunity Program (EDDOP) at Mount Sinai. In addition, she is a national leader in the NCTN both through her involvement in the GI committees of the Alliance for Clinical Trials in Oncology and the NRG Oncology, as well as her role as the co-chair of the NCI Gastrointestinal Steering Committee. She has nicely bridged the work she has done nationally with her institutional AD of Clinical Research position. She brings her expertise in clinical trial development and oversight which she gained as the National Study Chair of the CALGB/Alliance 80803, a Phase II trial that evaluated PET-directed therapy for esophageal cancer, and the National Radiation Oncology Principal Investigator of the RTOG/NRG 0848, a large Phase III trial investigating the role of adjuvant chemoradiation in resectable pancreas cancer. Her overarching goal as a senior leader in the TCI is to support the development of both IITs and NCI-funded cooperative group clinical trials that will further advance the fight against cancer. The R50 funding mechanism will undoubtedly help foster her ability to expand NCI-funded oncology clinical research at Mount Sinai Hospital and expand access to these trials across the MSHS. Dr. Goodman is uniquely positioned for this award with both her institutional and national service focused on developing and supporting cancer clinical research.